June 25, 2018
Former TiGenix CEO to lead Nordic Nanovector from July
Nordic Nanovector has appointed Vivet Therapeutic’s chairman and former TiGenix’s CEO, Eduardo Bravo as its new Chief Executive Officer, the…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: TiGenix
June 13, 2018
TiGenix’s CEO leaves as operations integrate into Takeda
TiGenix NV’s Chief Executive Officer, Eduardo Bravo will depart the board of directors and his role as CEO of TiGenix…
January 15, 2018
TiGenix’s Chron disease treatment get further validation
TiGenix’s result from study of Xx601 treatment for Chron’s disease has also been published in one of the leading scientific…
November 6, 2017
TiGenix converts €7M
TiGenix NV has converted €7 million of its senior unsecured convertible bonds due 2018. The company said that, through this…
November 2, 2017
Tigenix protects its Chron’s disease treatment
TiGenix has further strengthened its IP protection around the company’s lead product Cx601, intended for the treatment of complex perianal fistulas…
October 5, 2017
Tigenix to present positive Chron’s disease treatment testing results in Florida, USA
TiGenix NV has achieved positive results from its ADMIRE-CD Phase III clinical trial of Cx601 for the treatment of complex perianal…
September 12, 2017
TiGenix CEO welcomes two new team members in US
Belgian biopharmaceutical stem cells focused company TiGenix NV has made two senior appointments to reinforce its U.S. operations, who will both…
September 5, 2017
TiGenix gets more space at its expanded production facility in Madrid
TiGenix NV has obtained a license for the commercial production of expanded adipose-derived stem cells (eASCs) at its expanded manufacturing facility in Madrid.
June 20, 2017
Swissmedic to review Takeda, TiGenix’s Chron’s disease treatment Cx601
Takeda and TiGenix reported on Tuesday that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for review the file on investigational compound Cx601 to treat complex perianal fistulas in patients with Crohn’s disease.
June 15, 2017
TiGenix partners with Chron’s disease and ulcerative colitis broad advocacy groups
TiGenix has entered into a partnerships with the largest patient advocacy groups focused on Crohn’s disease and ulcerative colitis in the United States (US) and Europe.